Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Core Insights - Gain Therapeutics, Inc. is advancing its lead drug candidate GT-02287 for Parkinson's disease, with presentations scheduled at Neuroscience 2024 showcasing preclinical data [1][5] Group 1: Drug Candidate Information - GT-02287 is an allosteric protein modulator that targets the lysosomal enzyme glucocerebrosidase (GCase), which is affected by GBA1 mutations, a common genetic factor in Parkinson's disease [4] - Preclinical studies indicate that GT-02287 restores GCase function, reduces neuroinflammation, and improves motor and cognitive functions in Parkinson's disease models [4][5] - The drug has shown potential to slow disease progression, with significant improvements in cognitive and motor performance in mouse models [5] Group 2: Presentation Details - Two late-breaking poster presentations will occur on October 6, 2024, focusing on GT-02287's effects on Tau accumulation and mitochondrial function in Parkinson's disease models [2][3] - The presentations will be part of the Society for Neuroscience's annual event, highlighting the significance of the findings [1] Group 3: Funding and Support - Gain Therapeutics has received funding from The Michael J. Fox Foundation and The Silverstein Foundation, as well as support from the Eurostars-2 program and the European Union Horizon 2020 research initiative [6] Group 4: Company Overview - Gain Therapeutics is a clinical-stage biotechnology company specializing in the discovery of next-generation allosteric therapies, with GT-02287 currently in Phase 1 clinical trials [7] - The company utilizes an advanced drug discovery platform, Magellan™, which employs AI and machine learning to identify novel allosteric binding sites for drug development [8][9]